Literature DB >> 25252191

Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.

Qizhi Zheng1, Sarah B Peskoe, Judit Ribas, Fatema Rafiqi, Tarana Kudrolli, Alan K Meeker, Angelo M De Marzo, Elizabeth A Platz, Shawn E Lupold.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) are small non-coding RNAs that regulate a broad array of cellular and disease processes. Several miRNAs are differentially expressed in cancer and many are being considered as biomarkers for predicting clinical outcomes. Here we quantified the expression of three miRNAs, miR-21, miR-141, and miR-221, from prostate cancer surgical specimens and evaluated their association with disease recurrence after primary therapy.
METHODS: A pilot nested case-control study was designed from a large cohort of men who underwent radical prostatectomy between 1993 and 2001. Total RNA was extracted from malignant prostate tissue of 59 cases (recurrence) and 59 controls. Cases and controls were matched on age, race, pathologic stage, and grade. The relative expression of each miRNA was then determined for each sample by quantitative real-time RT-PCR. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of recurrence for tertiles of miRNA expression. We noted block storage time effects and thus, used separate tertile cutpoints based on the controls by calendar year of prostatectomy.
RESULTS: Lower miR-221 expression was associated with a higher risk of recurrence; the ORs were 3.21 for the lowest tertile and 2.63 for the middle tertile compared with the highest tertile of expression (P-trend = 0.02). This pattern was unchanged after multivariable adjustment (P-trend = 0.05). No statistically significant trends were observed for miR-21 or miR-141 after multivariable adjustment.
CONCLUSIONS: Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  biochemical recurrence; miR-141; miR-21; miR-221; microRNA; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 25252191      PMCID: PMC4205269          DOI: 10.1002/pros.22883

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  48 in total

Review 1.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

2.  Expression profiling identifies microRNA signature in pancreatic cancer.

Authors:  Eun Joo Lee; Yuriy Gusev; Jinmai Jiang; Gerard J Nuovo; Megan R Lerner; Wendy L Frankel; Daniel L Morgan; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen
Journal:  Int J Cancer       Date:  2007-03-01       Impact factor: 7.396

3.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

5.  Circulating microRNAs as stable blood-based markers for cancer detection.

Authors:  Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-28       Impact factor: 11.205

6.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.

Authors:  Stefan Ambs; Robyn L Prueitt; Ming Yi; Robert S Hudson; Tiffany M Howe; Fabio Petrocca; Tiffany A Wallace; Chang-Gong Liu; Stefano Volinia; George A Calin; Harris G Yfantis; Robert M Stephens; Carlo M Croce
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

8.  MicroRNA profile analysis of human prostate cancers.

Authors:  A W Tong; P Fulgham; C Jay; P Chen; I Khalil; S Liu; N Senzer; A C Eklund; J Han; J Nemunaitis
Journal:  Cancer Gene Ther       Date:  2008-10-24       Impact factor: 5.987

9.  MicroRNA expression profiling in prostate cancer.

Authors:  Kati P Porkka; Minja J Pfeiffer; Kati K Waltering; Robert L Vessella; Teuvo L J Tammela; Tapio Visakorpi
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 10.  miR-21: a small multi-faceted RNA.

Authors:  Anna M Krichevsky; Galina Gabriely
Journal:  J Cell Mol Med       Date:  2009-01       Impact factor: 5.310

View more
  26 in total

1.  Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis.

Authors:  Michael T Marrone; Corinne E Joshu; Sarah B Peskoe; Angelo M De Marzo; Christopher M Heaphy; Shawn E Lupold; Alan K Meeker; Elizabeth A Platz
Journal:  Clin Chem       Date:  2018-12-05       Impact factor: 8.327

2.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

3.  Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.

Authors:  Jian-Kai Yang; Ji-Peng Yang; Jing Tong; Shi-Yuan Jing; Bo Fan; Feng Wang; Guo-Zhu Sun; Bao-Hua Jiao
Journal:  J Neurooncol       Date:  2016-11-11       Impact factor: 4.130

4.  Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.

Authors:  Alicia C McDonald; Manish Vira; Vonn Walter; Jing Shen; Jay D Raman; Martin G Sanda; Dattatraya Patil; Emanuela Taioli
Journal:  Prostate       Date:  2019-04-08       Impact factor: 4.104

5.  Urinary MicroRNA Sensing Using Electrochemical Biosensor to Evaluate Colorectal Cancer Progression.

Authors:  Sow-Neng Pang; Yu-Lun Lin; Yueh-Er Chiou; Wai-Hung Leung; Wen-Hui Weng
Journal:  Biomedicines       Date:  2022-06-17

Review 6.  The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Authors:  Linda Fabris; Yvonne Ceder; Arul M Chinnaiyan; Guido W Jenster; Karina D Sorensen; Scott Tomlins; Tapio Visakorpi; George A Calin
Journal:  Eur Urol       Date:  2016-01-22       Impact factor: 20.096

7.  Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens.

Authors:  Sarah B Peskoe; John R Barber; Qizhi Zheng; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold
Journal:  BMC Cancer       Date:  2017-01-06       Impact factor: 4.430

8.  Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis.

Authors:  Ling Deng; Qianqian Lei; Yu Wang; Zhu Wang; Guiqin Xie; Xiaorong Zhong; Yanping Wang; Nianyong Chen; Yan Qiu; Tianjie Pu; Hong Bu; Hong Zheng
Journal:  Oncotarget       Date:  2017-10-06

9.  Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides.

Authors:  Javier A Baena-Del Valle; Qizhi Zheng; Jessica L Hicks; Helen Fedor; Bruce J Trock; Colm Morrissey; Eva Corey; Toby C Cornish; Karen S Sfanos; Angelo M De Marzo
Journal:  Am J Clin Pathol       Date:  2017-11-02       Impact factor: 2.493

10.  MiR-148a Functions as a Tumor Suppressor by Targeting CCK-BR via Inactivating STAT3 and Akt in Human Gastric Cancer.

Authors:  Beiqin Yu; Xin Lv; Liping Su; Jianfang Li; Yingyan Yu; Qinlong Gu; Min Yan; Zhenggang Zhu; Bingya Liu
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.